-
Sector Analysis
NewHydrogen Transition Market Outlook and Trends, Deals, Contracts, Policies, Projects and Key Players, Q2 2024
Hydrogen Transition Market Report Overview The total active and pipeline capacity of low-carbon hydrogen projects is 204 mtpa as of March 2024, of which 92% comes from green plants and the remaining from blue plants. Many regions of the world with ample renewable resources are pursuing large-scale green hydrogen projects to capitalize on the falling cost of producing renewable energy. Furthermore, the pipeline of upcoming green projects represents 1,374 GW of electrolyzer capacity, while upcoming blue projects would incorporate over...
-
Analyst Opinions
NewNorth America Energy Transition by Key Sectors and Companies Driving Development
North America Energy Transition Market Report Overview North America’s energy transition is continuing to gather pace, with a combination of technological development and favourable policy incentives driving substantial growth across renewables, hydrogen, and CCUS sectors. Technologies such as electric vehicles and renewable fuels are also experiencing increasing adoption albeit at a slower rate. The ‘North America Energy Transition’ market research report provides analysis and trends on North America’s energy transition from non-renewable to renewable sources. Key Power Types ·      Coal...
-
Analyst Opinions
Decarbonizing Maritime and Aviation Overview by Key Energy Transition Technologies and Case Studies, 2024 Update
Decarbonizing Maritime and Aviation Market Report Overview The automotive sector experiences a strong growth in demand for electric vehicles. However, the aviation and maritime sectors have been slow to decarbonize. To incentivize emission reductions, both sectors have set bold net-zero targets. However, according to the IEA, the sectors remain disoriented. Demand for cost-competitive and energy-dense fuels has led aviation and maritime to represent two of the most difficult to abate sectors. Both sectors will likely need to engage with a...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Margetuximab in Epithelial Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Margetuximab in Epithelial Ovarian Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Margetuximab in Epithelial Ovarian Cancer Drug Details: Margetuximab (Margenza) is a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cadonilimab in Rectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cadonilimab in Rectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cadonilimab in Rectal Cancer Drug Details: Cardinalizumab (Ketanil) is a bi-specific...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cadonilimab in Vulvar Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cadonilimab in Vulvar Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cadonilimab in Vulvar Cancer Drug Details: Cardinalizumab (Ketanil) is a bi-specific...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Enasidenib Mesylate in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Enasidenib Mesylate in Relapsed Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Enasidenib Mesylate in Relapsed Multiple Myeloma Drug Details: Enasidenib mesylate...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Enasidenib Mesylate in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Enasidenib Mesylate in Refractory Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Enasidenib Mesylate in Refractory Multiple Myeloma Drug Details: Enasidenib mesylate...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Certepetide in Bile Duct Cancer (Cholangiocarcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Certepetide in Bile Duct Cancer (Cholangiocarcinoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Certepetide in Bile Duct Cancer (Cholangiocarcinoma) Drug Details: Certepetide (CEND-1)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cadonilimab in Squamous Non-Small Cell Lung Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cadonilimab in Squamous Non-Small Cell Lung Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cadonilimab in Squamous Non-Small Cell Lung Carcinoma Drug...